Skip to content Skip to footer
Subscribe Now
NEWS

Lumos Labs Reports the US FDA Clearance of LumosityRx for ADHD Patients

Shots: The US FDA has granted 510(k) clearance to LumosityRx, a prescription digital therapeutic, designed to improve attention in adults (22-55yrs.) with attention deficit hyperactivity disorder (ADHD) Assessed in the GAMES Study (n>500), LumosityRx showed significantly improved TOVA Attention Comparison Score (1EP) vs a control app, with 44.2% pts achieving clinically meaningful attention gains (>1.4 points…
December 11, 2025

Read more

Tris Pharma
NEWS

Tris Pharma’s Onyda XR Gains the US FDA’s Approval for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) 

Shots:  The US FDA has granted approval to the company’s QD extended-release oral suspension of Onyda XR (clonidine hydrochloride) with nighttime dosing alone or as adj. to approved central nervous system (CNS) stimulant therapies for ADHD treatment in children (≥6yrs.). Its availability is anticipated in H2’24  The approval was supported by the data from studies…
May 29, 2024

Read more

ThoughtSpot_Carla Adams8
THOUGHTSPOT

ADHD Treatment Options: Therapy, Medication, and More

Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurological condition that affects both children and adults. It manifests as inattention, impulsivity, and hyperactivity that impact daily functioning and development. Finding the right treatment is crucial as it can greatly improve the individual's ability to function and their quality of life. Treatment options are diverse, ranging from various…
May 16, 2024

Read more